Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
Sandoz the global leader in generic and biosimilar medicines announced the filing of an antitrust lawsuit in the US against Amgen, Inc. , for extending and entrenching the dominant market position of its blockbuster medicine, Enbrel etanercept, first approved by the US Food and Drug Administration in 1998.